Preoperative oral pentoxifylline for management of cytokine reactions in cardiac surgery

Simple item page
dc.contributor.authorIskesen I.
dc.contributor.authorKurdal A.T.
dc.contributor.authorKahraman N.
dc.contributor.authorCerrahoglu M.
dc.contributor.authorSirin B.H.
dc.date.accessioned2024-07-22T08:21:39Z
dc.date.available2024-07-22T08:21:39Z
dc.date.issued2009
dc.description.abstractBackground: Cardiopulmonary bypass may lead to many inflammatory responses that may cause myocardial dysfunction after open heart surgery. We aimed to investigate the effect of preoperative pentoxifylline treatment to reduce the occurrence of cardiopulmonary bypass-induced inflammatory response. Methods: In a prospective, randomized study, 40 patients undergoing coronary artery bypass graft surgery received either pentoxifylline (study group, n = 21) or not (control group, n = 19). Pretreatment with pentoxifylline (800 mg/day orally) was started 5 days before the operation. Blood samples for measurements of tumor necrosis factor (TNF)-α, interleukin (IL)-6, IL-8 from the arterial line, and venous blood samples for creatine kinase (CK) and CK isoenzyme fraction MB (CK-MB) were taken in both groups at 5 different time points. Hemodynamic parameters were measured with the thermodilution technique. Results: TNF-α, IL-6, and IL-8 plasma levels increased in both groups after cardiopulmonary bypass, with a greater increase in the control group (P < .05). There were no significant differences between the groups for the values of CK-MB and hemodynamic parameters. Conclusions: We conclude that pretreatment with oral pentoxifylline before cardiac surgery inhibits proinflammatory cytokine release caused by cardiopulmonary bypass and has some beneficial effects in protecting the myocardium during the cardioplegic arrest period in open-heart surgery, without affecting postoperative hemodynamics. © 2009 Forum Multimedia Publishing, LLC.
dc.identifier.DOI-ID10.1532/HSF98.20081153
dc.identifier.issn15226662
dc.identifier.urihttp://akademikarsiv.cbu.edu.tr:4000/handle/123456789/18710
dc.language.isoEnglish
dc.subjectAdministration, Oral
dc.subjectCardiopulmonary Bypass
dc.subjectCytokines
dc.subjectFemale
dc.subjectFree Radical Scavengers
dc.subjectHumans
dc.subjectMale
dc.subjectMiddle Aged
dc.subjectMyocarditis
dc.subjectPentoxifylline
dc.subjectPremedication
dc.subjectPreoperative Care
dc.subjectTreatment Outcome
dc.subjectcreatine kinase
dc.subjectcreatine kinase MB
dc.subjectinterleukin 6
dc.subjectinterleukin 8
dc.subjectpentoxifylline
dc.subjecttumor necrosis factor alpha
dc.subjectcytokine
dc.subjectpentoxifylline
dc.subjectscavenger
dc.subjectadult
dc.subjectarterial blood
dc.subjectarticle
dc.subjectbiochemistry
dc.subjectblood sampling
dc.subjectcardioplegia
dc.subjectclinical article
dc.subjectclinical assessment
dc.subjectcontrolled study
dc.subjectcoronary artery bypass graft
dc.subjectcytokine release
dc.subjectdrug effect
dc.subjectfemale
dc.subjectheart protection
dc.subjecthemodynamic parameters
dc.subjecthuman
dc.subjectinflammation
dc.subjectmale
dc.subjectpreoperative treatment
dc.subjectpriority journal
dc.subjectprotein blood level
dc.subjectsurgical technique
dc.subjectthermodilution
dc.subjectvenous blood
dc.subjectblood
dc.subjectcardiopulmonary bypass
dc.subjectclinical trial
dc.subjectcontrolled clinical trial
dc.subjectmethodology
dc.subjectmiddle aged
dc.subjectmyocarditis
dc.subjectoral drug administration
dc.subjectpremedication
dc.subjectpreoperative care
dc.subjectrandomized controlled trial
dc.subjecttreatment outcome
dc.titlePreoperative oral pentoxifylline for management of cytokine reactions in cardiac surgery
dc.typeArticle

Files

Collections

Scopus Koleksiyonu